{
    "clinical_study": {
        "@rank": "75390", 
        "arm_group": {
            "arm_group_label": "Somatropin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the effect of\n      growth hormone on left ventricle morphology and function (systolic and diastolic)."
        }, 
        "brief_title": "Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency", 
        "completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Growth Hormone Disorder", 
            "Adult Growth Hormone Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult growth hormone deficiency\n\n          -  At least 2 years without growth hormone treatment\n\n        Exclusion Criteria:\n\n          -  Supine blood pressure above 160 mmHg systolic or above 100 mmHg diastolic\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698944", 
            "org_study_id": "GHDADULT-1112"
        }, 
        "intervention": {
            "arm_group_label": "Somatropin", 
            "description": "Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily", 
            "intervention_name": "somatropin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 3, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "Greece", 
                    "zip": "GR-11527"
                }
            }
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency", 
        "overall_official": {
            "affiliation": "Novo Nordisk Hellas Ltd.", 
            "last_name": "V. Fragoulopoulos, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Left Ventricular systolic function", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Left Ventricular diastolic function", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698944"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Body composition", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Fasting glucose", 
                "safety_issue": "No"
            }, 
            {
                "measure": "HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Oral glucose tolerance test (OGTT)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012", 
        "why_stopped": "The trial was prematurely terminated due to low recruitment"
    }
}